Skip to main content
. 2022 Nov 15;132(22):e161308. doi: 10.1172/JCI161308

Figure 6. Lung specific ablation of BCL6 inhibits KRAS-driven lung tumorigenesis.

Figure 6

(A) Schematic of experimental design. (B) Representative images of tumor from LSL-KrasG12D/+ mice: Bcl6+/+, Bcl6+/–, and Bcl6–/–. Micro-CT images showing axial planes of mouse lung. n = 7 per group. Tumor areas are indicated by red arrows. (C) Tumor volume of LSL-KrasG12D/+ mice: Bcl6+/+, Bcl6+/–, and Bcl6–/–. Quantification from micro-CT images represented in B. (D) Kaplan–Meier survival curves for LSL-KrasG12D/+ mice: Bcl6+/+, Bcl6+/–, and Bcl6–/–. n = 7 per group. (E) Representative H&E and IHC staining of lung from moribund LSL-KrasG12D/+ mice: Bcl6+/+, Bcl6+/–, and Bcl6–/–. n = 3 per group. Scale bars: 1 mm (inset), 50 μm (bottom). (F) Lesion classification of moribund LSL-KrasG12D/+ mice: Bcl6+/+, Bcl6+/–, and Bcl6–/–. n = 3 per group. Data in C and F are expressed as mean ± SEM of 3 technical replicates. Statistical analyses in C and F were performed using 1-way ANOVA with Tukey’s multiple comparison test, and in D using log-rank test, *P < 0.05, **P < 0.01, ***P < 0.001.